Pill Identifier App

PolyMedix Presents PMX-30063 Antibiotic Data at 8th World Congress on Trauma, Shock, Inflammation and Sepsis ? TSIS 2010

Session on Bacterial Drug Resistance, Superbugs, and the Need for New Antibiotics


 

RADNOR, Pa.--(BUSINESS WIRE)--Mar 11, 2010 - PolyMedix, Inc. (OTC BB: PYMX), an emerging biotechnology company focused on developing new therapeutic drugs to treat acute cardiovascular disorders and infectious diseases, has presented for the first time to the medical community data from its Phase 1B clinical study with its defensin-mimetic antibiotic compound, PMX-30063. The data were presented today at the 8th World Congress on Trauma, Shock, Inflammation and Sepsis (TSIS) in Munich, Germany. TSIS is a medical conference which focuses on the latest knowledge, developments and innovative concepts related to the recognition of disease as well as patient care and therapy within the wide field of acute and chronic systemic inflammation.


 

PolyMedix's Vice President of Clinical Development and Chief Medical Officer, Dr. Eric McAllister, presented during a session that focused on the problem of bacterial drug resistance to antibiotics, superbugs and the need for new antibiotic drugs. His presentation entitled, “An Approach to New Antibiotics for Avoiding Resistance: PMX-30063”, described the results to date from the Phase 1B dose-escalation clinical study which showed that the administration of multiple doses of PMX-30063 is safe and well-tolerated, with no clinically significant adverse effects at potential therapeutic dose levels. Dr. McAllister also presented data showing that PMX-30063 kills Staph bacteria, including MRSA, in human serum in blood samples drawn from study subjects at these same potential therapeutic dose levels.


 

PolyMedix's novel antibiotic compound, PMX-30063, is a small molecule mimetic of human host-defense proteins, one of the oldest and most effective antimicrobial defense systems found in virtually all living creatures. PMX-30063 has unique properties including a mechanism of action that is completely different from current antibiotic drugs. PMX-30063 directly disrupts the bacterial cell membrane, which is intended to make bacterial resistance unlikely to develop. In addition, it is fast acting and kills bacteria directly (bactericidal) rather than simply stopping bacterial reproduction (bacteriostatic, like many other antibiotic drugs). PMX-30063 is believed to be the first antibiotic with this mechanism of action being developed for use in systemic infections.


 

About PolyMedix, Inc.


 

PolyMedix is a publicly traded biotechnology company focused on the development of novel drugs and biomaterials for the treatment of acute cardiovascular disorders and infectious diseases. PolyMedix's compounds are based on biomimetics: non-peptide small molecule drug candidates and polymers that mimic the activity of proteins. PMX-60056, PolyMedix's heptagonist compound, is being developed to reverse the activity of both heparin and low molecular weight heparins. PolyMedix plans to develop an antagonist drug that is safer and easier to use than currently approved therapy. PMX-30063, PolyMedix's antibiotic compound is a small molecule that mimics human host-defense proteins and has a completely different mechanism of action distinct from those of current antibiotic drugs, a mechanism which is intended to make bacterial resistance unlikely to develop. PolyMedix's goal is to develop this compound as a rapidly acting antibiotic for serious systemic and local infections. Both PMX-60056 heptagonist and PMX-30063 antibiotic are currently undergoing clinical testing. PolyMedix also plans to continue the development of polymeric formulations as antimicrobial biomaterials, which can be used as additives to paints, plastics, and textiles to create self-sterilizing products and surfaces. For more information, please visit PolyMedix on its website at www.polymedix.com.


 

This press release contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 that involve risks, uncertainties and assumptions that could cause PolyMedix's actual results and experience to differ materially from anticipated results and expectations expressed in these forward looking statements. PolyMedix has in some cases identified forward-looking statements by using words such as “anticipates,” “believes,” “hopes,” “estimates,” “looks,” “expects,” “plans,” “intends,” “goal,” “potential,” “may,” “suggest,” and similar expressions. Among other factors that could cause actual results to differ materially from those expressed in forward-looking statements, PolyMedix's compounds may not enter or successfully complete clinical testing, or be granted regulatory approval to be sold and marketed in the United States or elsewhere. A more complete description of these risk factors is included in PolyMedix's filings with the Securities and Exchange Commission. You should not place undue reliance on any forward-looking statements. PolyMedix undertakes no obligation to release publicly the results of any revisions to any such forward-looking statements that may be made to reflect events or circumstances after the date of this press release or to reflect the occurrence of unanticipated events, except as required by applicable law or regulation.


 


 

Contact: Company:

PolyMedix, Inc.

Lisa Caperelli, 484-598-2406

lcaperelli@polymedix.com

or

Investors:

Erika Moran

emoran@investorrelationsgroup.com

or

Media:

The Investor Relations Group

Janet Vasquez, 212-825-3210

jvasquez@investorrelationsgroup.com


 

 


 

 

Posted: March 2010

View comments

Hide
(web1)